United Therapeutics upgraded to "buy"

02/21/07 - Pacific Crest Securities

NEW YORK, February 21 (newratings.com) - Analysts at Pacific Growth Equities upgrade United Therapeutics Corporation (UTHR) from "neutral" to "buy."

In a research note published yesterday, the analysts mention that sales of IV-Remodulin have grown faster than was earlier expected. United Therapeutics has indicated that sepsis did not have a significant impact on its 4Q06 results, and is unlikely to impact sales going ahead. The peak sales estimate has been raised from about $84 million to about $286 million. Enrollment in the company’s ongoing clinical trials has been more rapid than was anticipates, the analysts add.